Please assess the completion status of the following clinical trial:

Trial Title: Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* DISEASE CHARACTERISTICS: histologically confirmed breast cancer, locally advanced or metastatic disease, recurrent or refractory disease, histological or cytological confirmation required for recurrence in a solitary site~* Must have received prior anthracycline and taxane as neoadjuvant, adjuvant, or metastatic therapy~* At least 1 measurable site of disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan~* Palpable disease allowed, Lesions that have been irradiated in the advanced setting cannot be included as sites of measurable disease~* No nonmeasurable disease only, including the following:~* Bone lesions~* Leptomeningeal disease~* Ascites~* Pleural or pericardial effusion~* Inflammatory breast disease~* Lymphangitic pulmonary disease~* Abdominal masses that are not confirmed and followed by imaging techniques~* Cystic lesions~* No HER2-positive disease, defined as 3+ by IHC OR positive by FISH or chromogenic in situ hybridization~* Hormone receptor status not specified~* PATIENT CHARACTERISTICS:~* Male or female, Menopausal status not specified, ECOG performance status 0-1, Estimated life expectancy ≥ 12 weeks, Not pregnant or nursing, fertile patients must use effective contraception during and for 3 months after completion of study therapy~* ANC ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Hemoglobin ≥ 9 g/dL~* ALT or AST \< 2.5 times upper limit of normal (ULN)~* Bilirubin normal~* Alkaline phosphatase ≤ 2.5 times ULN~* Creatinine ≤ 1.25 times ULN OR creatinine clearance \> 40 mL/min~* Calcium ≤ 1.2 times ULN~* No concurrent serious medical or psychiatric illness, including any serious active infection incompatible with the study~* No other primary malignancy except carcinoma in situ of the cervix, adequately treated nonmelanomatous skin cancer, or any other malignancy previously treated ≥ 5 years ago with no evidence of recurrence~* No peripheral neuropathy ≥ grade 2~* PRIOR CONCURRENT THERAPY (See Disease Characteristics):~* Recovered from prior chemotherapy~* Prior hormonal therapy or immunotherapy allowed~* Antitumoral hormonal therapy must be discontinued prior to study entry~* More than 4 weeks since prior radiotherapy and recovered~* No prior radiotherapy to the whole pelvis or to ≥ 25% of the bone marrow~* No prior gemcitabine hydrochloride, cisplatin, or carboplatin~* No other cytotoxic chemotherapy for 21 days before and for 14 days after completion of study therapy~* More than 30 days since prior treatment with a drug (not including study drug) that has not received regulatory approval for any indication at the time of study entry~* Bisphosphonate therapy may not be initiated or discontinued within 4 weeks of study entry~* No more than 1 prior course of chemotherapy for metastatic disease~* Prior chemotherapy in the adjuvant setting allowed~* Concurrent palliative radiotherapy to existing painful lesions (soft tissue or bone) allowed~* New bone pain requiring radiotherapy \> 4 weeks after first study treatment considered disease progression~* New pain in a soft tissue lesion without other objective changes may be irradiated provided ≥ 1 other site of nonirradiated measurable disease exists~* No other concurrent anticancer treatment~* No concurrent tamoxifen citrate, aromatase inhibitors, or progestagens

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Patients with (HER-2)-negative and anthracycline- and taxane-resistant (Type: EXPERIMENTAL): Patients with human epidermal growth factor 2 (HER-2)-negative locally advanced or metastatic breast cancer that was anthracycline- and taxane-resistant

Based on this trial design, predict the completion outcome and termination type (if applicable).